Endocrine Abstracts

Care of patients (pts.) with hypoparathyroidism (HypoPT) is a challenge, because pts. are usually not treated with the absent hormone, but with several forms of vitamine D. We retrospectively evaluated the data of pts. with HypoPT in three endocrine centres in Germany.Methods: Records of 711 pts. with HypoPT (Centre 1 (C1): n=381, C2: n=253, C3: n=77) were reviewed (female: 592, male: 119). The following data under treatment (t...

Evaluation of bone quality represents a challenge since the analysis by bone mineral density (BMD), provides useful but incomplete information. New tools are arising, and amog them, TBS is emerging as a new surrogate marker of bone texture and microarchitecture which may be useful to potentially evaluate the risk of bone fracture and can be obtained from already existing BMD scans. Retrospective study of 23 patients with PHH. Clinical, analytical and BMD data were collected fo...

Thyroid hormones play a central role in the regulation of bone turnover and thyrotoxicosis is an established cause of secondary osteoporosis. Increased prevalence of reduced bone mineral density (BMD) has been reported even in patients with subclinical thyrotoxicosis such as those with differentiated thyroid carcinoma undergoing long-term L-thyroxine (L-T4) TSH-suppressive therapy. Morphometric vertebral fractures (VFs) are an early and clinically...

The ideal antiresorptive agent to preserve or further increase bone mineral density (BMD) following teriparatide treatment is not known. We aimed to compare BMD changes after one year of therapy with denosumab or bisphosphonates in osteoporotic patients who had completed treatment with teriparatide. We retrospectively analyzed 140 women (age 74 years, 26 years from menopause, BMI 27 kg/m2 on average) with severe postmenopausal osteoporosis who had been treated betwe...

Mutations of the calcium-sensing receptor (CaSR), G-protein alpha-11 subunit (Gα11), and adaptor protein-2 sigma subunit (AP2σ) resulting in a loss-of-function, cause familial hypocalciuric hypercalcemia types 1-3 (FHH1-3), respectively. We investigated a family with FHH (four affected and two unaffected members) for CaSR, Gα11 and AP2σ mutations, and identified a heterozygous Gα11 missense mutation, Phe220Ser, which is predicted to disrupt a cluster o...